1644

Attorney Docket: DX0388K3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
MAR 2 8 2003
TECH CENTER 1600/2900

MAR 2 [illegible] 2003

In re application of:

GOLSTEIN, et al.

Application No.: 09/929,612

Filed: August 13, 2001

For: PURIFIED MAMMALIAN CTLA-8 ANTIGENS AND RELATED REAGENTS

Examiner: Jessica H. Roark

Art Unit: 1644

Conf. No.: 9875

RESPONSE TO RESTRICTION REQUIREMENT

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on March 21, 2003.

by: Melanie Lyons

Commissioner for Patents
Washington, DC 20231

Honorable Sir:

This is a response to the Restriction Requirement dated February 24, 2003.

The Examiner restricted the application into eight separate inventions:

I. Claims 1-2 and 23-41, drawn to an isolated nucleic acid sequence [encoding] a mammalian CTLA protein wherein the nucleic acid is SEQ ID NO:1; vectors, host cells, and expression systems for producing the polypeptide, classified in Class 536, subclass 23.5; Class 435, subclasses 69.1, 455, 252.3, and 320.1.

II. Claims 1-2 and 23-41, drawn to an isolated nucleic acid sequence [encoding] a mammalian CTLA protein wherein the nucleic acid is SEQ ID NO:3; vectors, host cells, and expression systems for producing the polypeptide, classified in Class 536, subclass 23.5; Class 435, subclasses 69.1, 455, 252.3, and 320.1.

III. Claims 1-2 and 23-41, drawn to an isolated nucleic acid sequence [encoding] a mammalian CTLA protein wherein the nucleic acid is SEQ ID NOs:5 or 7; vectors, host cells, and expression systems for producing the polypeptide,

classified in Class 536, subclass 23.5; Class 435, subclasses 69.1, 455, 252.3, and 320.1.

IV. Claims 1-2 and 23-41, drawn to an isolated nucleic acid sequence [encoding] a mammalian CTLA protein wherein the nucleic acid is SEQ ID NO:9; vectors, host cells, and expression systems for producing the polypeptide, classified in Class 536, subclass 23.5; Class 435, subclasses 69.1, 455, 252.3, and 320.1.

V. Claims 42-45, drawn to a method of diagnosing patients suspected of having an abnormal condition by contacting a sample with a nucleic acid encoding a polypeptide at least 90% identical to SEQ ID NO:2, classified in Class 435, subclass 6.

VI. Claims 42-45, drawn to a method of diagnosing patients suspected of having an abnormal condition by contacting a sample with a nucleic acid encoding a polypeptide at least 90% identical to SEQ ID NO:4, classified in Class 435, subclass 6.

VII. Claims 42-45, drawn to a method of diagnosing patients suspected of having an abnormal condition by contacting a sample with a nucleic acid encoding a polypeptide at least 90% identical to SEQ ID NOs:6 or 8, classified in Class 435, subclass 6.

VIII. Claims 42-45, drawn to a method of diagnosing patients suspected of having an abnormal condition by contacting a sample with a nucleic acid encoding a polypeptide at least 90% identical to SEQ ID NO:10, classified in Class 435, subclass 6.

The Examiner further imposed a species election. If one of Groups V-VIII is elected, Applicants are required to elect between inflammation or a disorder involving cellular proliferation and between RNA or DNA.